/PRNewswire/ Acurx Pharmaceuticals (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 21,200 shares, a decrease of 7.0% from the April 30th total of 22,800 shares. Based on an average daily volume of 31,200 shares, the […]
Operator: Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2023 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded.
Acurx Pharmaceuticals (ACXP) Prices 1 33M Share Offering at $3/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
STATEN ISLAND, N.Y., May 16, 2023 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial. | May 16, 2023